Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Arbor plans to use the proceeds to advance its lead programs in liver and CNS disease into the clinic and progress a pipeline of precision editing therapeutics, while continuing to invest in its novel discovery engine to develop the next generation of gene editing technology.
Lead Product(s): Nuclease Therapies
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Arbor Biotechnologies, Inc
Deal Size: $215.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 09, 2021